Premium
Complementary laboratory indices for predicting the disease status of patients with hepatitis B virus infection
Author(s) -
Chen F.,
He J. L.,
Zheng M.,
Zhu H. H.,
Li S. P.,
Wang K.,
Zhang X. X.,
Zhao Y. R.,
Wu S. S.,
Chen Z.
Publication year - 2013
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12067
Subject(s) - immunology , hepatitis b virus , medicine , hepatitis a , hepatitis b , bilirubin , antibody , alanine transaminase , hepatitis , virus
Summary To identify complementary laboratory indices for determining the disease status of patients with hepatitis B virus. Subjects were divided into six groups: hepatitis B virus carrier, mild chronic hepatitis B, moderate chronic hepatitis B, severe chronic hepatitis B, fulminant hepatitis B and healthy controls. Serum alanine aminotransferase, total bilirubin and direct bilirubin were measured by an automatic analyser. The levels of T‐cell immunoglobulin domain and mucin‐domain‐containing molecule‐3, macrophage inflammatory protein 2, neutrophil gelatinase‐associated lipocalin and inducible nitric oxide synthase were measured by ELISA . T‐cell immunoglobulin domain, mucin‐domain‐containing molecule‐3, macrophage inflammatory protein 2 and inducible nitric oxide synthase levels were significantly higher in patients with severe chronic hepatitis B compared with those in patients with mild and moderate chronic hepatitis B or fulminant hepatitis B ( P < 0.05). When normal or abnormal alanine aminotransferase was present, significant differences between macrophage inflammatory protein 2 and T‐cell immunoglobulin domain and mucin‐domain‐containing molecule‐3 levels between patients with mild, moderate, severe chronic hepatitis B or fulminant hepatitis B were observed ( P < 0.05). Our results suggest that T‐cell immunoglobulin domain and mucin‐domain‐containing molecule‐3 and macrophage inflammatory protein 2 could serve as alanine aminotransferase, direct bilirubin or total bilirubin complementary indices for determining the status of patients with hepatitis B.